Selumetinib Sulfate in Treating Woman With Recurrent Low-Grade Ovarian Cancer or Peritoneum Cancer
Status:
Completed
Trial end date:
2020-11-13
Target enrollment:
Participant gender:
Summary
This phase II trial studies the side effects and how well selumetinib sulfate works in
treating patients with low-grade ovarian cancer that has come back (recurrent). Selumetinib
sulfate may stop the growth of tumor cells by blocking some of the enzymes needed for cell
growth.